

Effective December 1st, 2020 certain classes of medical benefit injectables covered under Medicare Part B will require step therapy. Each class of medical injectables will include preferred therapies that do not required prior authorization. Authorization for a non-preferred therapy will generally require history of use of a preferred therapy within the same medical benefit injectable class, among other criteria.

Note: The step therapy requirement does not apply to patients who have already received treatment with the non-preferred drug within the past 365 days.

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Acromegaly	Sandostatin LAR Signifor LAR Somavert	Somatuline Depot
Alpha-1 Antitrypsin Deficiency	Aralast Glassia Zemaira	Prolastin-C
Autoimmune	Actemra Cimzia Inflectra Orencia Renflexis	Entyvio Illumya Remicade Simponi Aria Stelara
Bevacizumab		Avastin Mvasi Zirabev
Botulinum Toxins	Myobloc	Botox Dysport Xeomin
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen Mircera Procrit	Aranesp Retacrit
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Granix Leukine Neupogen	Nivestym Zarxio
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Fulphila Ziextzenzo	Neulasta Udenyca
Lysosomal Storage Disorders – Gaucher Disease	Elelyso VPRIV	Cerezyme
Multiple Sclerosis (Infused)	Lemtrada	Tysabri
Osteoarthritis, Viscosupplements – Single Injection	Durolane Gel-One Monovisc	Synvisc-1

Osteoarthritis, Viscosupplements – Multi Injection	Euflexxa Gelsyn-3 Hyalgan Hymovis Supartz Visco-3	Orthovisc Synvisc
Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Agents	Firmagon Lupron Depot Trelstar Zoladex	Eligard
Retinal Disorders Agents	Lucentis Macugen Visudyne	Avastin Eylea
Rituximab		Rituxan Rituxan Hycela Ruxience
Trastuzumab	Herzuma Ogivri	Herceptin Herceptin Hylecta Kanjinti Trazimera